Open AccessGut microbiome composition can predict the response to nivolumab in advanced hepatocellular carcinoma patients
Author(s) -
Min-Woo Chung,
MoonJu Kim,
Eun Jeong Won,
Yu Jeong Lee,
Yong-Woon Yun,
Sung Bum Cho,
YoungEun Joo,
JunEul Hwang,
Woo Kyun Bae,
IkJoo Chung,
Myung Geun Shin,
Jong Hee Shin
Publication year - 2021
Publication title -
world journal of gastroenterology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.427
H-Index - 155
eISSN - 2219-2840
pISSN - 1007-9327
DOI - 10.3748/wjg.v27.i42.7340
Subject(s) - nivolumab , microbiome , hepatocellular carcinoma , enterococcus faecium , medicine , fusobacterium nucleatum , biology , immunotherapy , microbiology and biotechnology , cancer , bioinformatics , antibiotics , periodontitis , porphyromonas gingivalis
Immunotherapy has revolutionized the clinical outcomes of intractable cancer patients. Little is known about the intestinal nonpathogenic bacterial composition of hepatocellular carcinoma (HCC) patients treated by immunotherapy.